TA1041 (review of TA 662)
Durvalumab with Etoposide and either Carboplatin or Cisplatin for untreated extensive-stage small-cell lung cancer
Durvalumab with Etoposide and either Carboplatin or Cisplatin for untreated extensive-stage small-cell lung cancer